血管生成素对细胞核内功能的体外分析体系

利用人血管内皮细胞的细胞核而建立的体外转录分析体系可灵敏地定量测定血管生成素促进的RNA转录。反应体系中血管内皮细胞核先在缓冲液中与血管生成素混合 ,然后加四种核糖核苷三磷酸混合物启动反应 ,并以 [α 3 2 P]CTP作为示踪剂确定新生RNA的产量。结果显示 ,该体外分析体系的最适反应温度为 30℃ ,最佳反应时间是 30min ,在此反应条件下血管生成素可定量促进RNA转录 ,并存在着剂量效应。研究发现 ,体系中过高浓度的血管生成素降解RNA产物 ,提示细胞具有控制该因子在细胞核内积聚的生物学机制 ,以保证其在细胞内恰当地发挥作用。抑制血管生成素诱导的RNA转录可能可以抑制血管新生 ,因而可能是治疗肿瘤的一个新的分子靶。     

大肠杆菌核糖核酸酶调控机制研究

核糖核酸酶参与体内多种RNA代谢反应,对细菌生理功能调节起重要作用.细菌需要进化出多种策略来对体内核糖核酸酶进行调节,以避免对RNA进行不必要地降解.目前对大肠杆菌核糖核酸酶调节机制的研究包括转录后调控、翻译后修饰、细胞定位及相关抑制剂等.本文系统性地阐述了大肠杆菌核糖核酸酶的分类、功能及其体内调控机制,总结了不同环境...     

非编码RNA调控血管平滑肌细胞成骨样表型转化的研究进展

分化成熟的血管平滑肌主要功能是收缩血管、调节血管周径及血压等.在高磷、高糖、维生素D3、炎症等因素的作用下,平滑肌细胞可转分化为成骨样细胞参与血管钙化的形成,诱发心脑血管不良事件.非编码RNA是经基因转录但不翻译为蛋白质的一类RNA总称,其通过调控多种细胞活动来参与机体的生理和病理过程.已有研究表明,非编码RNA可通过调控血管平滑肌细胞成骨样表型转化影响血管钙化的发生、发展.本文从微小RNA、长链非编码RNA、环状RNA几方面综述非编码RNA在血管平滑肌成骨样表型转化中的调节作用,有助于进一步了解血管钙化的分子机制以及发现防治血管钙化的新靶点.     

代谢酶与RNA相互作用的研究进展

细胞代谢重编程对维持细胞稳态、细胞生长与增殖等细胞过程发挥着重要作用,并广泛参与恶性转化等病理过程。随着高通量分子检测技术的发展,人们发现有些代谢酶不仅能通过催化细胞内各种生化反应参与细胞代谢调控,同时还能结合RNA分子。这些代谢酶不具备经典的RNA结合域。已有研究显示它们可能通过一种负反馈机制调控其结合mRNA的运输、稳定性或翻译,从而将基因表达调控与细胞代谢联系起来。除此之外,酶的代谢产物也可能参与RNA与代谢酶相互作用的调控。重点从近年来发现的具备RNA结合能力的代谢酶、代谢酶与RNA的相互作用方式、RNA结合蛋白的鉴定与验证、代谢调控机制以及这些代谢酶与RNA相互作用如何调控复杂的细胞活动和疾病的发生发展过程进行综述。     

非编码RNA与细胞自噬调控

细胞自噬是真核生物细胞中高度保守的重要代谢途径。该途径是将细胞内有害或不需要的大分子分解并回收,从而使细胞在生长或环境改变导致的应激和压力条件下获得生存优势。近年越来越多的证据表明,非编码RNA,包括微RNA(microRNA,miRNA)和长非编码RNA(long non-coding RNA,lncRNA),在自噬过程中发挥了重要的作用。本文综述了miRNA和lncRNA在多种细胞环境中对细胞自噬的调控机制,并讨论了这些自噬相关的非编码RNA在疾病分子诊断、分类和预后中的作用,及其作为疾病治疗靶标的可能性。     

血管生成素研究的希望与挑战——浙江大学血管生成素研究

虽然血管生成素发现于1985年,但由于其性质上的特殊及研究条件的限制,人类对其功能的了解进展缓慢. 浙江大学血管生成素研究组建立于2001年,主要从蛋白质相互作用、基因转录调控、RNA代谢等层面研究血管生成素的功能机制,发现该蛋白能够与卵泡抑素、磷脂混杂酶1等蛋白质相互作用而细调rRNA的转录水平;在RNA转录中发挥表观遗传修饰调控因子作用;通过与细胞骨架相关蛋白的相互作用而促进细胞迁移;miR 409 3p通过直接靶向下调该蛋白的表达而发挥抑癌基因的作用. 同时,在模式生物斑马鱼中揭示了血管生成素同源基因对胚胎早期发育的影响. 本文全面回顾了我们14年来在血管生成素方面的研究进展,探讨了当前研究中存在的问题,并展望了未来的发展方向.     

三阴性乳腺癌中环状RNA的表达特点及功能意义

环状RNA是由前体RNA通过反向剪接形成的一类共价闭合环状分子。在过去,环状RNA被认为是DNA转录的"噪音",不参与生物代谢过程。然而,最近研究表明,环状RNA的异常表达可影响包括三阴性乳腺癌在内的多种恶性肿瘤的发生发展。该文综述了环状RNA在肿瘤中的分子机制及其在三阴性乳腺癌细胞增殖、凋亡、迁移、侵袭和药物抗性中的功能。     

RNA解旋酶和应激颗粒

应激颗粒（stress granules, SGs）是细胞在环境压力刺激下停止蛋白质翻译后,mRNA与多种细胞蛋白组装而成的胞质颗粒结构.RNA 解旋酶家族作为生物体内普遍存在的一类高度保守的蛋白质酶类,参与了RNA代谢各个环节,近年来其家族成员被陆续发现是一类新的SG重要组分.本文综述了RNA解旋酶参与应激颗粒形成过程,RNA解旋酶家族蛋白的结构和其参与应激颗粒形成的研究进展.     

动植物中RNA结合蛋白的研究进展

RNA结合蛋白(RNA-binding proteins)在转录后基因表达调节中起着重要的作用,它通过和RNA相互作用来调节细胞的功能。RNA结合蛋白参与RNA剪接、多聚腺苷化作用、序列编辑、RNA转运、维持RNA的稳定和降解、细胞内定位和翻译控制等RNA代谢的各个方面。主要介绍了RNA结合蛋白的结构、靶标RNA及RNA结合蛋白在动植物和疾病中的研究。     

核不均一性核糖核蛋白在RNA加工过程中的作用

在真核细胞中,初始转录产物（前体mRNA）经过一系列复杂的转录后加工过程形成成熟的mRNA.在这一过程中,大量蛋白质和加工因子有序汇集在核糖核蛋白复合体中并参与对前体RNA的加工过程. 该复合体中的蛋白质部分主要由一类约20种称为核不均一性核糖核蛋白的多肽分子构成.除了早期了解的一些结构性功能外,近来已有许多证据显示这些蛋白质在细胞中RNA的代谢及其他活动方面具有更加广泛和积极的作用.     

Angiogenin and Its Functions in Angiogenesis

The review is devoted to angiogenin, one of the factors that induce formation of blood vessels, which is unique in that it is a ribonuclease. Consideration is given to the tertiary structure of human angiogenin; the catalytic and cell receptor binding sites, their significance for angiogenic activity; the human angiogenin gene structure, chromosomal localization, and expression; the specificity of angiogenin as a ribonuclease and abolishment of protein synthesis; the nuclear localization of angiogenin in proliferating endothelial cells and its significance for angiogenic activity; angiogenin binding to cell surface actin as a plausible mechanism of inducing neovascularization (enhancement of plasminogen activation by actin, stimulation of the cell-associated proteolytic activity; promotion of the cultured cell invasiveness); modulation of mitogenic stimuli in endothelial, smooth muscle, and fibroblast cells by angiogenin. The importance of angiogenin as an adhesive molecule for endothelial and tumor cells is discussed too, as well as the modulation of tubular morphogenesis by bovine angiogenin, prevention of tumor growth in vivoby angiogenin antagonists, prospects of the use of angiogenin and angiogenin-encoding recombinant plasmids and vaccinia virus in therapeutic practice.     

Angiogenin and its role in angiogenesis]

The review is devoted to angiogenin, one of the factors that induce formation of blood vessels, which is unique among them in that it is a ribonuclease. Consideration is given to the tertiary structure of human angiogenin; the catalytic and cell-receptor binding sites, their significance for angiogenic activity; the human angiogenin gene structure, chromosomal localization, and expression; the specificity of angiogenin as a ribonuclease and abolishment of protein synthesis; the nuclear localization of angiogenin in proliferating endothelial cells and its significance for angiogenic activity; angiogenin binding to a cell-surface actin as a plausible mechanism of inducing neovascularization (enhancement of plasminogen activation by actin with angiogenin, stimulation of the cell-associated proteolytic activity by angiogenin; promotion of the cultured cells invasiveness); modulation of mitogenic stimuli in endothelial, smooth muscle, and fibroblast cells by angiogenin. The importance of angiogenin as an adhesive molecule for endothelial and tumor cells is discussed too, as well as the modulation of tubular morphogenesis by bovine angiogenin, prevention of tumor growth in vivo by angiogenin antagonists, prospects of the use of angiogenin and angiogenin-encoding recombinant plasmids and vaccinia virus in therapeutic practice.     

An in vitro binding assay for angiogenin using placental ribonuclease inhibitor

A convenient in vitro assay for angiogenin has been developed which greatly facilitates its routine detection and quantitation. The assay is based on the capacity of angiogenin to bind placental ribonuclease inhibitor (PRI); it is less tedious and more versatile than existing procedures that measure blood vessel growth or cleavage of rRNA. The test sample is added to a reaction mixture containing a known quantity of PRI, which complexes any angiogenin present in the sample. A slight excess of RNase A, relative to PRI, is then added, and the amount of RNase A which remains unbound is determined by measuring the generation of acid-soluble fragments from yeast RNA. The assay is sensitive to 30 fmol of angiogenin and is linear over a 17-fold concentration range. Use of the binding assay in parallel with a conventional RNase A assay provides a means of detecting angiogenin in chromatographic fractions and differentiating it from RNases. This procedure makes possible the isolation of angiogenin from new sources, such as nonhuman sera. It may also be applicable to other biologically active proteins with sequence homology to RNase A, e.g., eosinophil cationic protein or eosinophil derived neurotoxin.     

A covalent angiogenin/ribonuclease hybrid with a fourth disulfide bond generated by regional mutagenesis

Human angiogenin is a blood vessel inducing protein whose primary structure displays 33% identity to that of bovine pancreatic ribonuclease A (RNase A). Angiogenin catalyzes limited cleavage of 18S and 28S ribosomal RNA and is several orders of magnitude less potent than RNase A toward conventional substrates. A striking structural difference between angiogenin and RNase is the virtual absence of sequence similarity within the region of RNase that contains the Cys-65--Cys-72 disulfide bond. Indeed, angiogenin lacks this disulfide linkage. The present report describes the use of regional mutagenesis to generate a covalent angiogenin/RNase hybrid protein, ARH-I, where residues 58-70 of angiogenin have been replaced by the corresponding segment of RNase A (residues 59-73). The protein expressed in Escherichia coli readily folds at pH 8.5 to form the four expected disulfide bonds. The in vivo angiogenic potency of ARH-I is markedly diminished compared with that of angiogenin when examined using the chick chorioallantoic membrane assay. In contrast, its enzymatic activity is dramatically increased. With high molecular weight wheat germ RNA and tRNA, ARH-I is 660- and 300-fold more active than angiogenin, respectively, while with poly(uridylic acid), poly(cytidylic acid), cytidylyl(3'----5')adenosine (CpA), and uridylyl(3'----5')adenosine (UpA) activity is enhanced by about 200-fold. In addition, the specificity of ARH-I toward dinucleoside 3',5'-phosphates is qualitatively similar to RNase A; while angiogenin prefers cytidylyl(3'----5')guanosine (CpG) to UpA, both RNase and the hybrid prefer UpA to CpG. ARH-I also displays greater than 10-fold enhanced activity toward rRNA in intact ribosomes, while abolishing the capacity of the ribosome to support cell-free protein synthesis. The enhanced enzymatic properties of ARH-I parallel a 2-fold increase in chemical reactivity of active-site lysine and histidine residues based on rates of chemical modification. The data indicate that introduction of a region of RNase A containing the Cys-65--Cys-72 disulfide bond into angiogenin dramatically increases RNase-like enzymatic activity while reducing its angiogenicity.     

远端上游元件结合蛋白1的生物学功能

远端上游元件结合蛋白1（far upstream element binding protein 1, FUBP1）通过特异性结合远端上游元件（upstream element, FUSE）调控原癌基因c-Myc的转录。FUBP家族包括FUBP1、FUBP2、FUBP3及FUBP4,其序列具有高度同源性,但功能各不相同。FUBP1蛋白由3个结构域构成,具有两亲性螺旋结构的N端、富含酪氨酸的C端以及1个DNA结合区域。生理状态下,FUBP1蛋白定位于细胞核。除了调控c-Myc转录外,FUBP1还可结合RNA,参与调控mRNA稳定性、病毒复制及RNA的剪接。     

Green tea polyphenols as inhibitors of ribonuclease A

Ribonucleases (RNases), which are essential for cleavage of RNA, may be cytotoxic due to undesired cleavage of RNA in the cell. The quest for small molecule inhibitors of members of the ribonuclease superfamily has become indispensable with a growing number exhibiting unusual biological properties. Thus, inhibitors of RNases may serve as potential drug candidates. Green tea catechins (GTC), particularly its major constituent (-)-epigallocatechin-3-gallate (EGCG), have reported potential against cell proliferation and angiogenesis induced by several growth factors including angiogenin, a member of the RNase superfamily. This study reports the inhibition of bovine pancreatic ribonuclease A (RNase A) by EGCG and GTC. This has been checked qualitatively by an agarose gel based assay. Enzyme kinetic studies with cytidine 2',3' cyclic monophosphate as the substrate have also been conducted. Results indicate substantial inhibitory activity of a noncompetitive nature with an inhibition constant of approximately 80 microM for EGCG and approximately 100 microM for GTC measured in gallic acid equivalents.